IFNGR1 rs109049057: Maternal-Fetal Immune Signaling
The single nucleotide polymorphism rs109049057 is a common genetic variant situated in the IFNGR1 gene. Research links this variant to modulation of interferon-gamma receptor signaling, which plays a delicate regulatory role in maternal-fetal immune cross-talk during early gestation. Carrying this variant does not cause disease, but rather reflects subtle, population-level variability in cytokine pathway dynamics.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| CC | Carriers of two C alleles possess the reference baseline for interferon-gamma receptor expression at this locus. This common genotype is associated with standard receptor-mediated immune cross-talk at the maternal-fetal interface. It is considered an ordinary population baseline without known adverse effects. | Informational |
| CT | Heterozygous individuals carry one standard allele and one alternate allele. Studies suggest intermediate receptor signaling dynamics during immune interactions, consistent with typical physiological tolerance in general cohorts. This genotype does not cause known clinical deficiency or reproductive harm. | Informational |
| TT | Carrying two copies of the alternate T allele represents the homozygous minor genotype. Population research associates this state with altered interferon-gamma receptor signaling sensitivity during early gestational immune interactions. While it represents an area of ongoing scientific study, it remains a common variation that does not independently cause pregnancy loss or immune disease. | Informational |
Understanding rs109049057 and the IFNGR1 Gene
The rs109049057 polymorphism is located within the human IFNGR1 locus on chromosome 6. The IFNGR1 gene encodes the ligand-binding alpha chain of the heterodimeric interferon-gamma receptor complex, a cell-surface receptor expressed on various immune and non-immune cells. As documented in databases like [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/3459), binding of interferon-gamma (IFN-γ) to this receptor initiates downstream JAK-STAT signaling pathways that govern antimicrobial defense, cellular differentiation, and immune modulation. While severe loss-of-function mutations in IFNGR1 are known to cause Mendelian susceptibility to mycobacterial diseases, common polymorphisms like rs109049057 do not disrupt basic receptor integrity. Instead, non-coding and regulatory variants within this locus typically introduce slight variations in transcriptional efficiency or receptor density, subtly shaping how cells perceive and respond to circulating IFN-γ cues.
Maternal-Fetal Immune Cross-Talk and Receptor Dynamics
Successful early gestation requires a precisely orchestrated balance between maternal immune tolerance and local antimicrobial defense at the maternal-fetal interface. Decidual natural killer cells, macrophages, and trophoblasts constantly exchange cytokine signals, with interferon-gamma acting as a primary coordinator of uterine vascular remodeling and trophoblast invasion. Moderate scientific evidence associates rs109049057 with variations in interferon-gamma signaling intensity during early gestation, potentially influencing maternal-conceptus immune communication. If signaling is shifted too strongly toward inflammation or conversely toward excessive downregulation, the local endometrial cytokine environment may adapt differently during early pregnancy. Importantly, these findings reflect complex, polygenic trait associations across cohorts rather than monogenic determinants of reproductive outcomes, meaning that carrying a specific genotype represents a subtle baseline influence within a multifactorial biological system.
Evaluating Evidence Strength and Scientific Context
Scientific evidence linking rs109049057 to maternal-fetal immune adaptations is rated as moderate. Unlike high-penetrance clinical variants cataloged in [ClinVar](https://www.ncbi.nlm.nih.gov/clinvar/?term=rs109049057), common variations studied in maternal-fetal biology usually confer small effect sizes. Many maternal-fetal cross-talk studies face methodological complexities, including variable sample sizes, tissue-specific expression differences, and maternal-versus-fetal genetic interactions. Furthermore, immune regulation at the implantation site involves dozens of complementary cytokines, including interleukins and transforming growth factors, which can compensate for individual receptor variations. Therefore, current research provides an educational window into pathway biology rather than a definitive predictive biomarker for reproductive or immune complications.
Interpreting Your Results: Practical Implications
Discovering your rs109049057 genotype through consumer or research genetic testing provides insight into baseline biological variation, but it is not a clinical diagnosis or a direct indicator of pregnancy health. Genetic associations identified in population studies do not guarantee specific physiological outcomes, as maternal-fetal compatibility depends heavily on anatomical, systemic, and environmental factors. Individuals reviewing their results should not pursue unguided medical interventions, self-treatment, or diagnostic assumptions based solely on rs109049057. If you have personal questions regarding immune health, fertility, or pregnancy management, discuss them with a qualified obstetrician, reproductive endocrinologist, or genetic counselor who can evaluate your broader clinical history.
How common is this variant?
The minor allele frequency (MAF) for rs109049057 is approximately 0.29 across diverse reference cohorts according to catalog records, indicating that nearly half of the general population carries at least one copy of the variant allele.
Frequently asked questions
Does carrying the rs109049057 variant mean I will have pregnancy complications?
No. The variant rs109049057 is associated only with subtle, population-level variations in cytokine signaling and is not a clinical diagnostic marker. Pregnancy health is influenced by many complementary biological, clinical, and lifestyle factors.
What is the biological function of the IFNGR1 gene?
The IFNGR1 gene encodes the primary binding chain of the interferon-gamma receptor. This receptor allows immune and non-immune cells to detect interferon-gamma, initiating critical cellular signals for immune defense, inflammation management, and tissue remodeling.
Is rs109049057 linked to severe immune deficiency?
No. While rare, loss-of-function mutations in IFNGR1 can cause severe immunodeficiencies such as Mendelian susceptibility to mycobacterial diseases, rs109049057 is a common, non-destructive variant that does not disable receptor function.
Can I take medications or supplements to modify my IFNGR1 genotype?
No therapies exist or are required to change your inherited genetic makeup. Any medical or supplemental management related to immune function or pregnancy should always be discussed directly with your healthcare provider.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs109049057?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29